Behind Straumann’s Q1 Numbers. Digital Transformation and APAC Driving Growth.

Financial Performance:

- Total Revenue: CHF 644 million reported for Q1 2024.

- Organic Revenue Growth: 15.1% globally, translating to 8.1% when adjusted for currency impacts.

- Despite macroeconomic challenges, including high interest rates affecting patient flows, the company projects high single-digit revenue growth.

Regional Organic Revenue Overview:

- APAC: Reported a significant revenue increase of 82%.

 - China was highlighted for its strong growth.

- North America: Growth of 3.7%.

- Latin America: Revenue growth of 11.5%.

- EMEA: Increase of 5.2%.

Segment Performance:

- ClearCorrect: Achieved double-digit growth, exact figures weren't specified but indicated strong performance.

- Digital Business: Also reported double-digit growth, specifics not detailed but emphasized as a significant contributor to overall growth. 

Product Innovations & Digital Transformation:

- Continued enhancement of ClearCorrect, including a new version of ClearPilot.

- Launch of new high-performance iEXCEL premium implant system in North America.

- Alliedstar intraoral scanner launched in China with plans for future integration into the Straumann AXS platform.

- Investment in Straumann AXS to improve digital workflows and customer experience. 

Educational Initiatives:

- New educational center opened in Malaysia, part of the strategic push to increase penetration in the APAC region.

- Ongoing educational efforts particularly in under-penetrated markets like China.

Other Insights:

- Commitment to improving customer experience through digital workflows and operational efficiencies. 

- The high growth rate in China was attributed to the COVID-19 lockdowns in 2023 and the fact that the market is underpenetrated.

- Capacity expansions in the U.S. and China to support increased demand and operational efficiencies.